Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Laninamivir - Vaxart /Daiichi Sankyo

Next Previous
X
Search
Drug Profile

Laninamivir - Vaxart /Daiichi Sankyo

Alternative Names: CS-8958; Inavir; LANI; Laninamivir octanoate - Vaxart /Daiichi Sankyo; Laninamivir octanoate hydrate - Vaxart /Daiichi Sankyo; R-118958

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Daiichi Sankyo Company
  • Developer Daiichi Sankyo Company; Vaxart
  • Class Acetamides; Antivirals; Carboxylic acids; Esters; Guanidines; Pyrans; Small molecules
  • Mechanism of Action Neuraminidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 13 Feb 2018 Aviragen Therapeutics has merged with Vaxart forming Vaxart
  • 30 Jun 2017 Daiichi Sankyo completes a phase III trial for Influenza virus infections (In neonates, In infants, In children) in Japan (Inhalation) (JapicCTI-163398)
  • 30 Jun 2017 Daiichi Sankyo completes a phase III trial for Influenza virus infections (In children, In adolescents, In adults, In the elderly) in Japan (Inhalation) (JapicCTI-163397)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top